MelphalanMarrow TransplantationNewly diagnosedASCTDexamethasoneRelapsePeripheral-bloodTherapiesRefractory multipleCancerABSTRACTSymptomaticSystemicBoneMalignancyPrognosticHematopoietic stem and progenitor cellsPathologicClinicalTherapySurvivalEngraftmentImmunoTherapyBortezomibThalidomideHematologicTreatmentCyclophosphamideAntibodiesRemissionBioLineRxImmuneAdvancesLeukemiaHSCTMalignant plasma cellsTransplantsDiagnosisMBBSMonoclonalPlasmaComplications
Melphalan13
- In elderly patients or patients in whom autologous transplantation is not possible in the future, melphalan and prednisone (MP) therapy is preferred because of its ease of administration and low toxicity. (medscape.com)
- We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. (nature.com)
- High-dose melphalan followed by autologous stem cell transplant after induction has been associated with superior event-free survival compared with chemotherapy and is considered the preferred approach. (medscape.com)
- The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. (nih.gov)
- In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. (nih.gov)
- Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. (nih.gov)
- 1 Despite significant therapeutic advances for MM, autologous stem cell transplant (ASCT) following high-dose, single-agent melphalan conditioning remains a cornerstone of therapy. (haematologica.org)
- 2 The primary driver of response to ASCT is the depth of anti-myeloma activity of melphalan. (haematologica.org)
- Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy. (snmjournals.org)
- The study of 668 patients with newly-diagnosed multiple myeloma compared treatment with two courses of Celgene's Alkeran (melphalan) to the combination of Alkeran and Celgene's Thalomid brand of thalidomide alongside autologous stem cell transplantation. (pharmatimes.com)
- The results show that consolidation plus maintenance after either bortezomib, melphalan, and prednisone [VMP] or high-dose melphalan, autologous stem-cell transplantation [ASCT] deepens the response and significantly improves the PFS in comparison with maintenance alone," Sonneveld and colleagues wrote. (medpagetoday.com)
- High-dose melphalan followed by ASCT, as well as maintenance with lenalidomide, remain standard treatment for transplant-eligible patients with newly diagnosed multiple myeloma. (medpagetoday.com)
- In this study, patients received induction with 3 to 4 cycles of vincristine, cyclophosphamide, and dexamethasone, and mobilization of stem cells was performed, after which patients either underwent therapy with 4 cycles of VMP, or high-dose melphalan and single or double ASCT. (medpagetoday.com)
Marrow Transplantation11
- Biology of Blood and Marrow Transplantation , 18 (10), 1540-1551. (elsevierpure.com)
- Bone Marrow Transplantation , 36 (9), 793-796. (elsevierpure.com)
- Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
- Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
- Atkinson K, Meyers J, Storb R, Prentice RL, Thomas ED . Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. (nature.com)
- Infection with varicella-zoster virus after marrow transplantation. (nature.com)
- Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. (nature.com)
- Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. (nature.com)
- Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
- Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
- MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
Newly diagnosed9
- We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. (scielo.br)
- Review of 1027 patients with newly diagnosed multiple myeloma. (scielo.br)
- Design and Methods Oral cyclophosphamide, thalidomide, and dexamethasone was compared with infusional cyclophosphamide, vincristine, doxorubicin, and dexamethasone in patients with newly diagnosed multiple myeloma. (haematologica.org)
- Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma. (haematologica.org)
- High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
- Frailty score predicts outcome in transplant-ineligible patients with newly diagnosed myeloma and is incorporated into the staging criteria. (medscape.com)
- Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. (drugpatentwatch.com)
- Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm. (cancernetwork.com)
- Consolidation treatment with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRD) followed by maintenance with lenalidomide improved progression-free survival (PFS) and the depth of response compared with maintenance alone in transplant-eligible patients with newly diagnosed multiple myeloma, researchers found. (medpagetoday.com)
ASCT8
- The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
- Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
- We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
- The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). (nature.com)
- Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation ( P =0.009). (nature.com)
- Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ ( P =0.007). (nature.com)
- Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). (haematologica.org)
- Is HDT-ASCT the only option in the frontline for multiple myeloma treatment? (janssen.com)
Dexamethasone6
- Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. (stembook.org)
- It is indicated as monotherapy, in combination with dexamethasone, or in combination with lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in patients who have received at least 1 prior line of therapy. (medscape.com)
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (nih.gov)
- All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitor and dexamethasone). (medscape.com)
- There was an increased incidence of venous and arterial thrombotic events in patients with multiple myeloma who received lenalidomide in combination with dexamethasone compared with dexamethasone alone in clinical trials. (pdr.net)
- It is indicated in combination with bortezomib and dexamethasone for treatment of multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. (medscape.com)
Relapse2
- Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. (smw.ch)
- Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. (trialx.com)
Peripheral-blood4
- In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
- A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitory cell transplantation. (nature.com)
- The FDA has approved motixafortide (Aphexda) combined with filgrastim (G-CSF) to aid in mobilizing hematopoietic stem cells in the peripheral blood for collection, as well as succeeding autologous stem cell transplantation in a population with multiple myeloma, according to a press release from BioLineRx. (cancernetwork.com)
- Several drug therapies are valuable in the treatment of symptomatic MM. Clinicians treat many patients with high-dose therapy and peripheral blood or bone marrow stem cell transplantation. (medscape.com)
Therapies9
- High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies. (elsevierpure.com)
- In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
- antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. (trialx.com)
- Innovation in this area of medicine has been needed, and today's approval of [motixafortide] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization, [vs] filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with this cancer. (cancernetwork.com)
- Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma. (onclive.com)
- After his disease went into remission again, this patient has now received 2 different T-cell-redirection therapies when those remissions ended. (onclive.com)
- Historically, in multiple myeloma, to receive accelerated approval for a new drug for patients with an unmet need (ie, those who had exhausted all available therapies), you needed a 20% to 30% response rate for 3 to 4 months. (onclive.com)
- Now we have game-changing T-cell-redirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies," he explained. (onclive.com)
- T-cell-redirection therapies are now giving anywhere from 60% to 100% response rates that are lasting upward of 9 months to we don't even know how long, because they're so durable. (onclive.com)
Refractory multiple2
- Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. (nih.gov)
- This case is a patient with refractory multiple myeloma autologous stem cell transplantation and continuous chemotherapy with immune dysfunction. (flu.org.cn)
Cancer23
- Evidence indicates that residual cancer cells contaminate autologous grafts and may contribute to early relapses after autologous stem cell transplantation. (elsevierpure.com)
- Large numbers of myeloid-derived suppressor cells (MDSCs), a mixture of monocytic and granulocytic cells, accumulate during many pathologic conditions, including cancer, infectious diseases, trauma, and sepsis. (biomedcentral.com)
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
- Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
- Multiple myeloma is a blood cancer that starts in the plasma cells in the bone marrow. (medlineplus.gov)
- As the cancer cells grow in the bone marrow, you may have bone pain, most often in the ribs or back. (medlineplus.gov)
- The cancer cells can weaken bones. (medlineplus.gov)
- Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
- Our scientific fraternity achieved a lot this year in the field of cancer treatment, giving new ray of hope to cancer patients with advances in immunotherapy, stem cell transplants and genomic testing. (trialx.com)
- FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. (trialx.com)
- It reprograms the body's own immune system to recognise and kill cancer cells. (trialx.com)
- The therapy initially called CAR-T cell immunotherapy and now named Kymriah by Novartis, is approved to treat children and young adults with a recurrent form of the blood cancer called acute lymphoblastic leukemia (ALL). (trialx.com)
- The discussion highlighted the opportunity that these engineered immune cells present to cancer treatment and possible use in treatment of other cancers. (trialx.com)
- We talked to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. (trialx.com)
- Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
- By blocking the CXCR4 receptor, motixafortide was shown in a Phase 2 study in pancreatic cancer patients to enhance anti-tumoral activity and to ameliorate the pro-tumoral activities by modulating the effector/suppressor cell ratio towards a proinflammatory profile. (fox5sandiego.com)
- Dimeo FC, Tilmann MH, Bertz H, Kanz L, Mertelsmann R, Keul J: Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (karger.com)
- Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
- Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe [motixafortide] will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer," Serlin stated. (cancernetwork.com)
- Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice. (cancernetwork.com)
- This study was supported by the Dutch Cancer Society, the European Myeloma Network, and by unrestricted grants from Celgene and Janssen. (medpagetoday.com)
- RÉSUMÉ Le myélome multiple est un cancer systémique caractérisé par des cellules plasmatiques anormales, qui peut être traité par des agents chimiothérapeutiques et par irradiation, mais qui est rarement curable. (who.int)
- Multiple myeloma (MM) is a cancer of the The largest series, 23 patients with lepto- plasma cells. (who.int)
ABSTRACT1
- ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
Symptomatic2
- Patients who present with active (symptomatic) multiple myeloma are treated with induction therapy. (medscape.com)
- Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
Systemic3
- This ex vivo rabbit-specific oncolytic poxvirus called myxoma virus treatment also effectively inhibits systemic in vivo engraftment of human myeloma cells into immunodeficient mice and results in efficient elimination of primary CD138 + myeloma cells contaminating patient hematopoietic cell products. (elsevierpure.com)
- In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
- However, due to complex and varied systemic symptoms, including inflammatory storm, sepsis, acute respiratory failure, tachycardia, coagulopathy, and other extrapulmonary organ injuries, she died 19 days after signs due to severe respiratory failure and multiple organ failure. (flu.org.cn)
Bone9
- Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
- Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
- The bone marrow makes blood cells. (medlineplus.gov)
- In people with multiple myeloma, abnormal plasma cells grow out of control in the bone marrow and form tumors in the areas of solid bone. (medlineplus.gov)
- It also makes it harder for the bone marrow to make healthy blood cells and platelets. (medlineplus.gov)
- An autologous bone marrow or stem cell transplantation is performed using a person's own stem cells. (medlineplus.gov)
- Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
- Malignant plasma cells in meningeal MM out of 2000 patients with bone marrow produce an immunoglobulin, MM, was reported was by Schluterman et al. (who.int)
- The prevalence production, lytic lesions and increased of leptomeningeal infiltration in breast can- plasma cells in the bone marrow [ 1 ]. (who.int)
Malignancy3
- Multiple myeloma (MM) represents 1% of all cancers and is the second most common hematologic malignancy, after lymphoma. (scielo.br)
- Multiple Myeloma (MM) is an incurable plasma cell malignancy that accounts for 18% of all hematologic malignancies. (haematologica.org)
- Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
Prognostic1
- Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. (elsevierpure.com)
Hematopoietic stem and progenitor cells3
- Here, we demonstrate that ex vivo treatment with an oncolytic poxvirus called myxoma virus results in specific elimination of human myeloma cells by inducing rapid cellular apoptosis while fully sparing normal hematopoietic stem and progenitor cells. (elsevierpure.com)
- The specificity of this elimination is based on strong binding of the virus to myeloma cells coupled with an inability of the virus to bind or infect CD34 + hematopoietic stem and progenitor cells. (elsevierpure.com)
- Early fate decisions in hematopoietic stem and progenitor cells. (lu.se)
Pathologic2
- Thirty-eight patients (4.83%) had pathologic findings before transplantation. (slideshare.net)
- A 59-year-old man with a history of IgG kappa multiple myeloma presented to an outpatient facility for evaluation of left hip pain, which was found to be a pathologic fracture. (medscape.com)
Clinical4
- NCCN clinical practice guidelines in oncology: multiple myeloma. (medlineplus.gov)
- Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. (nature.com)
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. (smw.ch)
- Ajai Chari, MD, professor of medicine and the director of clinical research in the multiple myeloma (MM) program at the Icahn School of Medicine at Mount Sinai in New York, NY, saw an opportunity to contribute from the earliest days of the COVID-19 pandemic. (onclive.com)
Therapy14
- Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
- The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
- The approval of new drugs continues to change the landscape of myeloma maintenance therapy. (medscape.com)
- Alkylator and nitrosourea therapy is usually deferred or reduced in patients who may require autologous stem cell collection, to avoid injury to the stem cells. (medscape.com)
- Post-transplantation maintenance therapy with low-dose lenalidomide yields improved PFS and overall survival (OS). (medscape.com)
- The intrinsic immune dysfunction in combination with therapy-related immunosuppression leads to an increased risk for infections, which is a hallmark of multiple myeloma (MM) and major cause of mortality [ 1 - 5 ]. (jcancer.org)
- Minimal residual disease (MRD) refers to the small number of malignant cells that remain after therapy when the patient is in remission and shows no symptoms or overt signs of disease. (smw.ch)
- We discussed Dr. Junes CAR-T cell journey to understand nuances of the new therapy. (trialx.com)
- Listen to the talk on CAR- T cell therapy with Dr. June HERE! (trialx.com)
- In 2017 stem cell transplants remains a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done as a part of frontline therapy. (trialx.com)
- Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. (trialx.com)
- Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received. (cancernetwork.com)
- Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments. (cancernetwork.com)
- Cell Replacement Therapy for Parkinson's Disease - Evaluating the potential of autologous grafting. (lu.se)
Survival4
- Multivariable analysis revealed that creatinine ≥2 mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. (scielo.br)
- Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation. (scielo.br)
- Outcome and survival of myeloma patients diagnosed 2008-2015. (scielo.br)
- Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an incurable disease with a median survival of approximately 30 months. (drugpatentwatch.com)
Engraftment1
- The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
ImmunoTherapy3
- Multiple Myeloma on CureTalks in 2017: CAR T Cell Immunotherapy, Stem Cell Transplants, MRD Testing, MMRF Precision Medicine Model and More. (trialx.com)
- Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. (trialx.com)
- Hear Dr. Saad Usmani discuss new advances in immunotherapy in myeloma treatment HERE! (trialx.com)
Bortezomib1
- Bortezomib is indicated for patients with multiple myeloma. (medscape.com)
Thalidomide2
- The damage caused by thalidomide was not mutually exclusive, with the majority of children exhibiting damage to multiple organs and tissues [ 3 , 7 ]. (hindawi.com)
- Last year, Celgene was forced to discontinue a trial of a thalidomide derivative - Revlimid (lenalidomide) - in multiple myeloma patients after patients developed blood clots. (pharmatimes.com)
Hematologic1
- elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
Treatment17
- We conclude that ex vivo myxoma treatment represents a safe and effective method to selectively eliminate myeloma cells from hematopoietic autografts before reinfusion. (elsevierpure.com)
- It is indicated for the palliative treatment of multiple myeloma. (medscape.com)
- Plasma cell neoplasms (including multiple myeloma) treatment (PDQ) - health professional version. (medlineplus.gov)
- Treatment protocols for multiple myeloma are provided below. (medscape.com)
- The myeloma panel talked to Dr. Rafael Fonseca for answers to these and more on the latest developments in stem cell transplant technology in multiple myeloma treatment. (trialx.com)
- The myeloma panelists talked to Dr. Ola Landgren, a lead researcher in the field at MSK , about how MRD testing could become a new and earlier end-point in myeloma treatment. (trialx.com)
- Listen Dr. Landgren share what MRD testing could mean to your myeloma treatment HERE! (trialx.com)
- The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
- Yet, to some this drug is a lifesaver, as it now enjoys renaissance in the treatment for a wide range of conditions including leprosy, multiple myeloma, Behcet's disease, and some cancers. (hindawi.com)
- Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attributed to conventional myeloablative transplant regimens. (drugpatentwatch.com)
- Donor immunization with myeloma Id in the setting of a non-myeloablative allogeneic SCT may represent a novel strategy for the treatment of multiple myeloma. (drugpatentwatch.com)
- To determine the treatment-related morbidity and mortality of allogeneic stem cell transplantation using a non-myeloablative conditioning regimen in multiple myeloma. (drugpatentwatch.com)
- The latter drug was approved for another haematological disease, myelodysplastic syndromes - in December 2005, and has been fast-tracked as a multiple myeloma treatment by the US Food and Drug Administration (FDA). (pharmatimes.com)
- In 2005, the FDA issued an approvable letter for Thalomid in the treatment of multiple myeloma, asking for additional information on the drug. (pharmatimes.com)
- Janssen EMEA › The 'gold standard' of first-line treatment in multiple myeloma - is it time for a rethink? (janssen.com)
- For the multiple myeloma (MM) community , these words ring true with every treatment breakthrough that is made: they are actions that bring new hope as we work towards a cure. (janssen.com)
- The 'gold standard": What is the current recommended treatment for newly diasnosed multiple myeloma? (janssen.com)
Cyclophosphamide1
- Secondary Objectives: To evaluate the effect of the Fludarabine-(etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide) EPOCH regimen on host T cell depletion and myeloid depletion prior to allogeneic SCT. (drugpatentwatch.com)
Antibodies2
- Plasma cells help your body fight infection by producing proteins called antibodies . (medlineplus.gov)
- A type and antibody screen specimen obtained before the transfusions revealed that his red cells were type B positive, a screen for unexpected antibodies was negative, and direct antibody tests (DAT) for both anti-IgG and anti-C3b were also negative. (medscape.com)
Remission1
- Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. (smw.ch)
BioLineRx1
- BioLineRx announces FDA approval of APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma. (cancernetwork.com)
Immune3
- MDSCs are characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [ 7 ]. (biomedcentral.com)
- Motixafortide leverages the expression of the CXCR4 receptor on different immune cells and potentiates the immune system against the tumor. (kron4.com)
- Among CXCR4-expressing immune cells, some exhibit anti-tumoral activity, such as effector T cells and some exhibit pro-tumoral activity and support tumor growth. (fox5sandiego.com)
Advances1
- Stem Cell Research Advances , edn. (edu.au)
Leukemia3
- Patients with monoclonal gammopathy of unknown significance, smoldering MM, plasma cell leukemia and amyloidosis were excluded. (scielo.br)
- [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
- Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms related to cytopenias. (msdmanuals.com)
HSCT1
- His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
Malignant plasma cells2
- Furthermore, the infection itself can pathogenetically contribute to the progression of MM through different mechanisms, such as robust production of promyeloma cytokines (e.g., interleukin-6) and activation of Toll-like receptors on malignant plasma cells [ 6 - 10 ]. (jcancer.org)
- First described in 1848, MM is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein (M protein). (medscape.com)
Transplants2
- Research shows that stem cell transplants significantly increases the amount of time, for which a patient has their disease under control. (trialx.com)
- He has had 2 autologous stem cell transplants, 7 years and 1 year ago. (medscape.com)
Diagnosis2
- Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. (scielo.br)
- The diagnosis was established according to International Myeloma Working Group criteria [ 12 ]. (jcancer.org)
MBBS1
- Chari's longtime mentor and colleague Sundar Jagannath, MBBS, director of the Center of Excellence for Multiple Myeloma at Mount Sinai, believes his mentee's work on this study sums up Chari very well. (onclive.com)
Monoclonal1
- Monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. (medscape.com)
Plasma1
- Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
Complications2
- The cer is about 2%-5% and as high as 26% in most common complications include renal small-cell lung carcinoma [ 5 ]. (who.int)
- Two weeks before the current visit, he received a transfusion of 2 units of red blood cells to treat anemia , but complications were documented. (medscape.com)